We Offer Worldwide Shipping
Login Wishlist

Acetylisocupressic acid

$1,216

  • Brand : BIOFRON

  • Catalogue Number : BN-O1586

  • Specification : 98%(HPLC)

  • CAS number : 52992-82-2

  • Formula : C22H34O4

  • Molecular Weight : 362.5

  • PUBCHEM ID : 6440360

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1586

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

362.5

Appearance

Powder

Botanical Source

This product is isolated and purified from the barks of Araucaria cunninghami

Structure Type

Diterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC(=CCOC(=O)C)CCC1C(=C)CCC2C1(CCCC2C(=O)OC)C

Synonyms

1-Naphthalenecarboxylic acid, 5-[(3E)-5-(acetyloxy)-3-methyl-3-penten-1-yl]decahydro-1,4a-dimethyl-6-methylene-, (1S,4aR,5S,8aR)-/(1S,4aR,5S,8aR)-5-[(3E)-5-Acetoxy-3-methyl-3-penten-1-yl]-1,4a-dimethyl-6-methylenedecahydro-1-naphthalenecarboxylic acid/1-Naphthalenecarboxylic acid, 5-((3E)-5-(acetyloxy)-3-methyl-3-pentenyl)decahydro-1,4a-dimethyl-6-methylene-, (1S,4aR,5S,8aR)-

IUPAC Name

methyl (1S,4aR,5S,8aR)-5-[(E)-5-acetyloxy-3-methylpent-3-enyl]-4a-methyl-6-methylidene-1,2,3,4,5,7,8,8a-octahydronaphthalene-1-carboxylate

Density

1.1±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

153.7±20.3 °C

Boiling Point

471.4±38.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

MGQMYSVCEMGOPL-WQTQMUQDSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:52992-82-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

20067621

Abstract

Background
Stripe rust of wheat, caused by Puccinia striiformis f. sp. tritici (Pst), is one of the most important diseases of wheat worldwide. Due to special features of hexaploid wheat with large and complex genome and difficulties for transformation, and of Pst without sexual reproduction and hard to culture on media, the use of most genetic and molecular techniques in studying genes involved in the wheat-Pst interactions has been largely limited. The objective of this study was to identify transcriptionally regulated genes during an incompatible interaction between wheat and Pst using cDNA-AFLP technique

Results
A total of 52,992 transcript derived fragments (TDFs) were generated with 64 primer pairs and 2,437 (4.6%) of them displayed altered expression patterns after inoculation with 1,787 up-regulated and 650 down-regulated. We obtained reliable sequences (>100 bp) for 255 selected TDFs, of which 113 (44.3%) had putative functions identified. A large group (17.6%) of these genes shared high homology with genes involved in metabolism and photosynthesis; 13.8% to genes with functions related to disease defense and signal transduction; and those in the remaining groups (12.9%) to genes involved in transcription, transport processes, protein metabolism, and cell structure, respectively. Through comparing TDFs identified in the present study for incompatible interaction and those identified in the previous study for compatible interactions, 161 TDFs were shared by both interactions, 94 were expressed specifically in the incompatible interaction, of which the specificity of 43 selected transcripts were determined using quantitative real-time polymerase chain reaction (qRT-PCR). Based on the analyses of homology to genes known to play a role in defense, signal transduction and protein metabolism, 20 TDFs were chosen and their expression patterns revealed by the cDNA-AFLP technique were confirmed using the qRT-PCR analysis.

Conclusion
We uncovered a number of new candidate genes possibly involved in the interactions of wheat and Pst, of which 11 TDFs expressed specifically in the incompatible interaction. Resistance to stripe rust in wheat cv. Suwon11 is executed after penetration has occurred. Moreover, we also found that plant responses in compatible and incompatible interactions are qualitatively similar but quantitatively different soon after stripe rust fungus infection.

Title

Differential gene expression in incompatible interaction between wheat and stripe rust fungus revealed by cDNA-AFLP and comparison to compatible interaction

Author

Xiaojie Wang,1 Wei Liu,1 Xianming Chen,2 Chunlei Tang,1 Yanling Dong,1 Jinbiao Ma,1 Xueling Huang,1 Guorong Wei,1 Qingmei Han,1 Lili Huang,1 and Zhensheng Kangcorresponding author1

Publish date

2010;

PMID

29744873

Abstract

Background
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non‐serious adverse events.

Objectives
To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non‐randomised studies.

Search methods
In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 12 other databases and two trials registers. We also checked reference lists and contacted authors and pharmaceutical companies to identify additional studies.

Selection criteria
We included non‐randomised study designs. These comprised comparative and non‐comparative cohort studies, patient‐control studies, patient reports/series and cross‐sectional studies of methylphenidate administered at any dosage or formulation. We also included methylphenidate groups from RCTs assessing methylphenidate versus other interventions for ADHD as well as data from follow‐up periods in RCTs. Participants had to have an ADHD diagnosis (from the 3rd to the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders or the 9th or 10th edition of theInternational Classification of Diseases, with or without comorbid diagnoses. We required that at least 75% of participants had a normal intellectual capacity (intelligence quotient of more than 70 points) and were aged below 20 years. We excluded studies that used another ADHD drug as a co‐intervention.

Data collection and analysis
Fourteen review authors selected studies independently. Two review authors assessed risk of bias independently using the ROBINS‐I tool for assessing risk of bias in non‐randomised studies of interventions. All review authors extracted data. We defined serious adverse events according to the International Committee of Harmonization as any lethal, life‐threatening or life‐changing event. We considered all other adverse events to be non‐serious adverse events and conducted meta‐analyses of data from comparative studies. We calculated meta‐analytic estimates of prevalence from non‐comparative cohorts studies and synthesised data from patient reports/series qualitatively. We investigated heterogeneity by conducting subgroup analyses, and we also conducted sensitivity analyses.

Main results
We included a total of 260 studies: 7 comparative cohort studies, 6 of which compared 968 patients who were exposed to methylphenidate to 166 controls, and 1 which assessed 1224 patients that were exposed or not exposed to methylphenidate during different time periods; 4 patient‐control studies (53,192 exposed to methylphenidate and 19,906 controls); 177 non‐comparative cohort studies (2,207,751 participants); 2 cross‐sectional studies (96 participants) and 70 patient reports/series (206 participants). Participants’ ages ranged from 3 years to 20 years. Risk of bias in the included comparative studies ranged from moderate to critical, with most studies showing critical risk of bias. We evaluated all non‐comparative studies at critical risk of bias. The GRADE quality rating of the evidence was very low.

Primary outcomes

In the comparative studies, methylphenidate increased the risk ratio (RR) of serious adverse events (RR 1.36, 95% confidence interval (CI) 1.17 to 1.57; 2 studies, 72,005 participants); any psychotic disorder (RR 1.36, 95% CI 1.17 to 1.57; 1 study, 71,771 participants); and arrhythmia (RR 1.61, 95% CI 1.48 to 1.74; 1 study, 1224 participants) compared to no intervention.

In the non‐comparative cohort studies, the proportion of participants on methylphenidate experiencing any serious adverse event was 1.20% (95% CI 0.70% to 2.00%; 50 studies, 162,422 participants). Withdrawal from methylphenidate due to any serious adverse events occurred in 1.20% (95% CI 0.60% to 2.30%; 7 studies, 1173 participants) and adverse events of unknown severity led to withdrawal in 7.30% of participants (95% CI 5.30% to 10.0%; 22 studies, 3708 participants).

Secondary outcomes

In the comparative studies, methylphenidate, compared to no intervention, increased the RR of insomnia and sleep problems (RR 2.58, 95% CI 1.24 to 5.34; 3 studies, 425 participants) and decreased appetite (RR 15.06, 95% CI 2.12 to 106.83; 1 study, 335 participants).

With non‐comparative cohort studies, the proportion of participants on methylphenidate with any non‐serious adverse events was 51.2% (95% CI 41.2% to 61.1%; 49 studies, 13,978 participants). These included difficulty falling asleep, 17.9% (95% CI 14.7% to 21.6%; 82 studies, 11,507 participants); headache, 14.4% (95% CI 11.3% to 18.3%; 90 studies, 13,469 participants); abdominal pain, 10.7% (95% CI 8.60% to 13.3%; 79 studies, 11,750 participants); and decreased appetite, 31.1% (95% CI 26.5% to 36.2%; 84 studies, 11,594 participants). Withdrawal of methylphenidate due to non‐serious adverse events occurred in 6.20% (95% CI 4.80% to 7.90%; 37 studies, 7142 participants), and 16.2% were withdrawn for unknown reasons (95% CI 13.0% to 19.9%; 57 studies, 8340 participants).

Authors’ conclusions
Our findings suggest that methylphenidate may be associated with a number of serious adverse events as well as a large number of non‐serious adverse events in children and adolescents, which often lead to withdrawal of methylphenidate. Our certainty in the evidence is very low, and accordingly, it is not possible to accurately estimate the actual risk of adverse events. It might be higher than reported here.

Given the possible association between methylphenidate and the adverse events identified, it may be important to identify people who are most susceptible to adverse events. To do this we must undertake large‐scale, high‐quality RCTs, along with studies aimed at identifying responders and non‐responders.

Title

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non‐randomised studies

Author

Ole Jakob Storebø,corresponding author Nadia Pedersen, Erica Ramstad, Maja Lærke Kielsholm, Signe Sofie Nielsen, Helle B Krogh, Carlos R Moreira‐Maia, Frederik L Magnusson, Mathilde Holmskov, Trine Gerner, Maria Skoog, Susanne Rosendal, Camilla Groth, Donna Gillies, Kirsten Buch Rasmussen, Dorothy Gauci, Morris Zwi, Richard Kirubakaran, Sasja J Hakonsen, Lise Aagaard, Erik Simonsen, and Christian Gluud

Publish date

2018 May

PMID

30979144

Abstract

Three new Ag(I) and one Cu(I) coordination compounds with two different positional isomers, propane-1,3-diyl bis(pyridine-4-carboxylate) (L1) and propane-1,3-diyl bis(pyridine-3-carboxylate) (L2), of a bis-(pyridyl-carboxylate) ligand have been synthesized. X-ray diffraction analysis revealed that the self-assembly of L1 with AgCF3SO3 and AgClO4 salts leads to the formation of discrete binuclear metallocycles {Ag(L1)CF3SO3}2 (1) and {Ag(L1)ClO4}2 (2), respectively. However, self-assembly of the other ligand, L2, with AgCF3SO3 and CuCl salts, results in a 1-D zig-zag chain {Ag(L2)CF3SO3}∞ (3) and a 1-D double-stranded helical chain {Cu2Cl2(L2)2}∞ (4) coordination polymers, respectively. Solid emission spectra recorded at room temperature show interesting luminescence properties for all four compounds in the range from 438 to 550 nm, especially for compound 4 that was found to change its emission color when the wavelength of the excitation radiation is switched from 332 to 436 nm.

KEYWORDS

metal-organic framework, luminescence, coordination polymer, MOF

Title

Self-Assembly of Discrete Metallocycles versus Coordination Polymers Based on Cu(I) and Ag(I) Ions and Flexible Ligands: Structural Diversification and Luminescent Properties

Author

Javier Vallejos,1 Ivan Brito,2,* Alejandro Cardenas,3 Michael Bolte,4 Sergio Conejeros,5 Pere Alemany,5 and Jaime Llanos1

Publish date

2016 Feb


Description :

Empty ...